Sanofi US and Regeneron Pharmaceuticals have reported positive results from the first Phase II trial of alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), for the treatment of patients with low-density lipoprotein-cholesterol (LDL-C).

The results showed that the mean LDL-C percentage reduction from baseline to week 12, the primary efficacy endpoint, was significantly greater in patients randomised to receive one of three doses of alirocumab administered every other week (Q2W) 150mg, 75mg, and 50mg, in combination with statin therapy, compared with patients receiving placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

At week 12, the mean percentage reduction in LDL-C from baseline in patients receiving dosage of alirocumab 50mg, 75mg and 150mg was 55%, 62% and 72% respectively, compared to 3% in the placebo group.

The company said that all patients in each of the alirocumab groups achieved LDL-C levels of <100 mg/dL, compared to 8% of patients in the placebo group.

"The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients."

Treatment emergent adverse events (TEAEs) in the trial were reported by 52% of patients in the alirocumab 50mg group, 48% of patients in the 75mg group, 64% of patients in the 150mg group, compared with 32% in the placebo group.

See Also:

Most frequently reported TEAEs were nasopharyngitis, injection site reaction, back pain, cystitis and ligament sprain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sanofi Group head of the PCSK9 development and launch unit Jay Edelberg said: "Not only was alirocumab shown, in this study, to significantly reduce LDL-C in this patient population, the results of this study also demonstrate the potential efficacy of alirocumab at a range of doses."

The multicentre, placebo-controlled Phase II trial randomised about 100 patients with LDL-C greater than or equal to 100mg/dL receiving lipid-modifying therapy.

Regeneron chief scientific officer and Regeneron Laboratories president George Yancopoulos said hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins.

"The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients," Yancopoulos said.

According to the company, PCSK9 is said to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-C from the blood.

Alirocumab is an investigational, fully-human monoclonal antibody discovered by Regeneron Pharmaceuticals and is currently being co-developed by Regeneron and Sanofi.